TORRANCE, Calif.--(BUSINESS WIRE)--Celprogen Inc., a leader in the Stem Cell Research and Therapeutics
industry for stem cell research since 2002, today announced that they
have successfully finished printing a 3D Pancreas from flexible Poly
Lactic Acid (PLA) material scaffold that was populated with adult human
pancreatic stem cells.
These 3D printed human pancreases were coated and seeded with human
adult pancreatic stem cells. The 3D pancreas scaffold was populated with
three T225 human Pancreatic Stem Cells 36097-24-T225, and with human
adult pancreatic cells 3002-04-T225; the scaffold was coated with ECM
prior to seeding the cells. This flexible PLA scaffold allows the seeded
pancreatic stem cells to potentially differentiate into an adult
functional pancreas. The 3D print was reduced from an adult 18 year old
pancreas to approximately 1/5 its original size.
The present invention relates to 3D organ printing programs at Celprogen
that identify potential future use in transplants of major organ
systems. At present Celprogen is validating the 3D human printed heart
from flexible PLA, and also the pancreas. The 3D printed heart is being
presented at the American Society of Cell Biology Annual meeting next
week in San Francisco, California. The 3D printed heart is utilized as a
model for screening potential drug candidates for cardiac toxicity.
About Celprogen Inc.
Celprogen Inc. is a global Stem Cell Research & Therapeutics company
since 2002, which is developing a proprietary portfolio of unique
therapeutics products and life science research tools that includes
genetic engineering technologies, stem cell technologies for
regenerative medicine, as well as bio-engineering products for tissue &
organ transplants. Headquartered in Torrance, California, Celprogen is
committed to the research, development, and manufacture of quality Stem
Cell, Cancer Stem Cell and Primary Cell Culture products to serve our
global community. Additional information about Celprogen is available at http://www.celprogen.com.